ZE46-0134 (lomonitinib)

About Eilean Therapeutics

Eilean Therapeutics is a private, preclinical-stage biotech targeting treatment-resistant hematological cancers through a pipeline of novel small molecules. Its strategy centers on developing 'pan-variant' inhibitors that address multiple resistance mutations and escape pathways simultaneously, aiming to create more durable therapies. The company has a broad early pipeline targeting high-value oncogenic drivers like FLT3/IRAK4, BCL2, and Menin, with its most advanced program, a JAK2 V617F inhibitor, having entered first-in-human studies. Backed by experienced leadership and venture capital investors like OrbiMed, Eilean is positioned to tackle a significant unmet need in oncology.

Therapeutic Areas

Other AML Drugs